Intranasal Administration of a Therapeutic HIV Vaccine (Vacc-4x) Induces Dose-Dependent Systemic and Mucosal Immune Responses in a Randomized Controlled Trial


BACKGROUND Vacc-4x, a Gag p24-based therapeutic HIV vaccine, has been shown to reduce viral load set-points after intradermal administration. In this randomized controlled pilot study we investigate intranasal administration of Vacc-4x with Endocine as adjuvant. METHODS Safety and immunogenicity were tested in patients on effective ART. They were… (More)
DOI: 10.1371/journal.pone.0112556

6 Figures and Tables


  • Presentations referencing similar topics